Recent Advances in Liver Transplantation

Wiesner, Russell H.; Rakela, Jorge; Ishitani, Michael B.; Mulligan, David C.; Spivey, James R.; Steers, Jeffery L.; Krom, Ruud A.F.
February 2003
Mayo Clinic Proceedings;Feb2003, Vol. 78 Issue 2, p197
Academic Journal
Provides information on advances in liver transplantation. Problem with shortages in donor organs; Changes in the liver allocation policy; Concern over recurrent disease, particularly hepatitis C; Use of pegylated interferon in combination with ribavirin to prevent recurrence of hepatitis C; Recommendation for tailoring immunosuppressive regimens to the individual patient.


Related Articles

  • Strategies for Optimizing Immunosuppression in Adolescent Transplant Recipients: A Focus on Liver Transplantation. Kelly, D.A. // Pediatric Drugs;2003, Vol. 5 Issue 3, p177 

    Adolescence is a difficult time for transplant recipients; they must learn to take responsibility for their own behavior and medication, and to balance their developing sexuality in a body that has been transformed by the adverse effects of immunosuppression. More than 80% of children survive...

  • Pediatric liver transplantation. Spada, Marco; Riva, Silvia; Maggiore, Giuseppe; Cintorino, Davide; Gridelli, Bruno; Torbenson, Michael // World Journal of Gastroenterology;2/14/2009, Vol. 15 Issue 6, p648 

    In previous decades, pediatric liver transplantation has become a state-of-the-art operation with excellent success and limited mortality. Graft and patient survival have continued to improve as a result of improvements in medical, surgical and anesthetic management, organ availability,...

  • Intensivtherapie nach Transplantation solider Organe. Lichtenstern, C.; Müller, M.; Schmidt, J.; Mayer, K.; Weigand, M.A. // Anaesthesist;Dec2010, Vol. 59 Issue 12, p1135 

    Transplantation medicine is an interdisciplinary task and the priority objective is a fast recovery to patient independence. After kidney transplantation the crucial aims are monitoring of transplant perfusion, maintainance of an adequate volume status and avoidance of nephrotoxic medications....

  • Pharmacokinetics of Mycophenolic Acid and Determination of Area Under the Curve by Abbreviated Sampling Strategy in Chinese Liver Transplant Recipients. Hao Chen; Chenghong Peng; Zhicheng Yu; Baiyong Shen; Xiaxing Deng; Weihua Qiu; Yue Fei; Chuan Shen; Guangwen Zhou; Weiping Yang; Hongwei Li // Clinical Pharmacokinetics;2007, Vol. 46 Issue 2, p175 

    Objectives: This study aimed to: (i) define the clinical pharmacokinetics of mycophenolic acid (MPA) in Chinese liver transplant recipients; and (ii) develop a regression model best fitted for the prediction of MPA area under the plasma concentration-time curve from 0 to 12 hours (AUC12) by...

  • The History Of Liver And Renal Transplantation. Tolou Ghamari, Z.; Palizban, A.A. // Internet Journal of Pharmacology;2003, Vol. 2 Issue 1, p24 

    The Shiraz Nemazi transplant centre was the pioneer transplant unit of Iran, which performed the first kidney transplant in 1967 by Ghods and the first liver transplant by Malek Hosseini in 1995 (¹,²). In this article we review the history of both, liver and renal transplantations.

  • Oral Diseases and Liver Pre and Post-Transplantation Disorders. Lins Kusterer, Liliane Elze Falcão // Journal of Transplantation Techniques & Research;Special2012, Vol. 2 Issue S, p1 

    Cirrhotic patients with a poor state of oral health, particularly those with chronic infections, may have an increased susceptibility to systemic infections in pre and post liver transplantation. The literature correlates a poor state of oral health with liver cirrhosis, possibly leading to a...

  • Features of HCV recurrence in patients with HCV - related cirrhosis after liver transplantation and its antiviral and immunomodulatory therapies. JIAO Jian; WANG Jiangbin // Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi;2014, Vol. 30 Issue 1, p14 

    The best choice of treatment for patients with HCv-related cirrhosis may be liver transplantation once liver decompensation occurs. Immunoregulatory drugs, especially immunosuppressants, may be a main causative factor for accelerated HCv recurrence after liver transplantation. How to control HCv...

  • Tolerogenic therapies in transplantation. Page, Eugenia K.; Dar, Wasim A.; Knechtle, Stuart J. // Frontiers in Immunology;Jul2012, Vol. 3, p1 

    Since the concept of immunologic tolerance was discovered in the 1940s, the pursuit of tolerance induction in human transplantation has led to a rapid development of pharmaco-logic and biologic agents. Short-term graft survival remains an all-time high, but successful withdrawal of...

  • Weaning transplant recipients from their immunosuppressive drugs.  // Biomedical Market Newsletter;12/14/2011, Vol. 21, p1 

    The article provides information on a research conducted at University of Barcelona, Spain identifying markers that could wean transplant recipients from immunosuppressive drugs. Transplant recipients takes drugs life long to prevent rejection of their transplanted organ having side effects....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics